Keros Therapeutics, Inc. (KROS)

Keros Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 25, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Cap	224	398	642	1,266	1,323	1,403
Market Cap Growth	-49.50%	-38.02%	-49.29%	-4.28%	-5.71%	-14.26%
Enterprise Value	-46.94	124.97	98.93	948.29	1,056	1,173
Last Close Price	11.34	20.36	15.83	39.76	48.02	58.51
PE Ratio	4.93	8.85	-3.17	-7.65	-11.57	-23.22
PS Ratio	0.92	1.63	180.84	8384.12	-	69.79
PB Ratio	0.73	1.31	1.12	3.81	4.77	5.77
P/TBV Ratio	1.42	2.54	1.04	3.52	4.37	5.61
P/FCF Ratio	2.11	3.76	-3.94	-9.97	-18.55	-22.21
P/OCF Ratio	2.08	3.70	-3.99	-10.17	-18.88	-22.57
EV/Sales Ratio	-	0.51	27.87	6280.09	-	58.36
EV/EBITDA Ratio	-	1.81	-0.47	-5.61	-9.26	-20.95
EV/EBIT Ratio	-	1.85	-0.47	-5.58	-9.20	-20.81
EV/FCF Ratio	-	1.18	-0.61	-7.47	-14.82	-18.57
Debt / Equity Ratio	0.05	0.05	0.03	0.04	0.05	0.00
Debt / EBITDA Ratio	0.10	0.24	-0.09	-0.08	-0.12	-0.02
Debt / FCF Ratio	0.16	0.16	-0.12	-0.11	-0.19	-0.02
Net Debt / Equity Ratio	-0.89	-0.89	-0.95	-0.95	-0.96	-0.94
Net Debt / EBITDA Ratio	-1.63	-3.92	2.58	1.87	2.33	4.09
Net Debt / FCF Ratio	-2.55	-2.55	3.32	2.49	3.73	3.62
Asset Turnover	0.51	0.51	0.01	0.00	0	0.08
Quick Ratio	14.36	14.36	20.50	13.59	16.86	20.94
Current Ratio	15.45	15.45	21.45	14.25	17.27	21.23
Return on Equity (ROE)	45.16%	19.90%	-41.46%	-50.19%	-40.21%	-23.27%
Return on Assets (ROA)	35.28%	14.92%	-42.70%	-50.22%	-40.85%	-20.73%
Return on Invested Capital (ROIC)	533.44%	225.61%	-915.33%	-1251.82%	-887.57%	-985.85%
Return on Capital Employed (ROCE)	36.29%	14.92%	-45.14%	-53.45%	-43.02%	-22.30%
Earnings Yield	38.92%	11.30%	-31.59%	-13.08%	-8.64%	-4.31%
FCF Yield	47.39%	26.63%	-25.36%	-10.03%	-5.39%	-4.50%
Buyback Yield / Dilution	94.17%	94.17%	-61.10%	-14.14%	-9.10%	-2.04%

Updated Mar 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q